Revolutionizing Regenerative Medicine: Exploring the Promise and Challenges of Allogeneic Therapies

Phacilitate
28 November 2023
SHARE NOW
Allogeneic
ATE
Cell Therapy
Raw Materials
David Sourdive joins us in this interview filmed at Advanced Therapies Europe 2023 discussing allogeneic therapies.
In this interview, David Sourdive, Executive Vice President CMC & Manufacturing at Cellectis explores the potential and challenges of allogeneic therapies as part or revolutionizing regenerative medicines. David also talks about the advantages of donor-derived therapies that pertain to manufacturing therapies.
This interview was recorded at Advanced Therapies Europe 2023.
More like this
Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor
This case study showcases the successful expansion of mesenchymal stem cells (MSCs) using Rooster Bio’s xeno-free MSC platform in Univercells Technologies’ scale-X fixed-bed bioreactor. The collaboration highlights seamless process transfer, rapid cell attachment, optimized harvesting with high viability (>96%), and robust scalability from R&D to GMP manufacturing. Key innovations include predictive bioprocess monitoring with Scalia Vision and cost-effective solutions for advanced therapy manufacturing.
10 February 2023
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies
We caught up with Patrick M Gailliot, Sr. Director, Patient Operations at Abeona Therapeutics, to talk to him about why his work gives him so much joy, preview his session at Advanced Therapies Week in Dallas, and explain the value he gets from the event.
26 November 2024